Targeting neuroinflammation: 3-monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration

Targeting neuroinflammation: 3-monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration

Abstract Background Traumatic Brain Injury (TBI) is a major risk factor for neurodegenerative disorders such as Parkinson’s disease (PD) and Alzheimer’s disease (AD), with neuroinflammation playing a critical role in the secondary cell death that exacerbates the initial injury. While targeting neuro...

Full description

Saved in:
Bibliographic Details
Main Authors: Shih Chang Hsueh, Pathik Parekh, Buyandelger Batsaikhan, Neil Vargesson, David Tweedie, Weiming Luo, Chirag N. Patel, Dong Liu, Ross A. McDevitt, Abdul Mannan Baig, Yu Kyung Kim, Sun Kim, Inho Hwang, Juwan Kim, Mee Youn Lee, Anna R. Carta, Warren R. Selman, Barry J. Hoffer, Dong Seok Kim, Nigel H. Greig
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Journal of Biomedical Science
Subjects:
Neuroinflammation
Immunomodulatory imide drugs (IMiDs)
Neurodegeneration
Microglia
Teratogenicity
Pomalidomide
Online Access:https://doi.org/10.1186/s12929-025-01150-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12929-025-01150-w

Similar Items